Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1372 • ACR Convergence 2024
Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Loarce³, Leticia del Olmo Perez⁴, Sara García-Pérez⁵, Guillermo Gonzalez Mozo de Rosales⁶, José Rosas-Gómez de Salazar⁷, Ana Urruticoechea-Arana⁸, Andrea García-Valle⁹, Juan Moreno Morales¹⁰, María Martín López¹¹, Patricia Lopez Viejo¹², Virginia Ruiz-Esquide¹³, Julia Fernandez Melon¹⁴, David Castro-Corredor¹⁵, Ana Fernández-Ortiz¹⁶, Rafael Benito Melero-Gonzalez¹⁷, Carolina Díez Morrondo¹⁸, Desiree Palma¹⁹, Natividad del Val del Amo²⁰, Natalia Mena Vázquez²¹, Alicia García Dorta²², MARÍA JOSÉ PÉREZ GALÁN²³, MARINA SOLEDAD MORENO GARCIA²⁴ and Ricardo Blanco-Alonso²⁵, and on behalf of JAKi in Interstitial Lung Disease Associated with Rheumatoid Arthritis, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴HOSPITAL NUESTRA SEÑORA DEL PRADO, TALAVERA DE LA REINA, Spain, ⁵Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ⁸Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital General Río Carrión, Palencia, Spain, ¹⁰Hospital Universitario Santa Lucia Cartagena, Murcia, Murcia, Spain, ¹¹General University Hospital of Ciudad Real, Ciudad de México, Spain, ¹²Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Hospital Son Espases, Palma, Spain, ¹⁵General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹⁶Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁷CHU Ourense, O Carballino, Spain, ¹⁸Complejo Asistencial Universitario de Leon, Leon, ¹⁹Hospital Rafael Méndez, Lorca, Murcia, Spain, ²⁰Complejo Hospitalario de Navarra, Pamplona, Spain, ²¹IBIMA, Málaga, Andalucia, Spain, ²²Rheumatologist, La Laguna, Spain, ²³SERVICIO ANDALUZ DE SALUD, GRANADA, Andalucia, Spain, ²⁴Hospital Universitario Miguel Servet, GIJON, Asturias, Spain, ²⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 1389 • ACR Convergence 2024
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Amy Peeters¹, Maike Wientjes², Wieland Müskens¹, David Ten Cate³, Bart van den Bemt⁴, Noortje van Herwaarden¹ and Alfons den Broeder², ¹Sint maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…
Abstract Number: 1647 • ACR Convergence 2024
Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission
Cornelia H. Quaack¹, Esther Röder¹, Hetty M. Wintjes¹, Anneke J. van Steensel-Boon¹, Annemarie G.M.G.J. Mulders², Laura C.J. Kranenburg-van Koppen¹ and radboud J.e.m. Dolhain¹, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Time to conception, known as time to pregnancy (TTP), is prolonged in women diagnosed with RA. High rates of infertility, defined as the inability…
Abstract Number: 1714 • ACR Convergence 2024
Avoidable Hospitalizations by Persons with Rheumatoid Arthritis: A Population-Based Study Using Administrative Data
Dani Contreras¹, Claire Barber¹, J. Antonio Avina-Zubieta², Hude Quan¹, Seungwon Lee¹, James King¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Ambulatory care sensitive conditions (ACSCs) are conditions where appropriate access to ambulatory care can reduce hospitalizations. People with rheumatoid arthritis (RA) are at higher…
Abstract Number: 1849 • ACR Convergence 2024
Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Theodora Manolakou¹, Sanjaykumar Boddul¹, George Sentis², Michail Angelos Panagias¹, Martina Samiotaki³, Dionysis Nikolopoulos¹, Ana Slipicevic¹, Kumar Sanjiv¹, Martin Henriksson¹, Oliver Mortusewicz¹, Aikaterini Chatzidionysiou¹, Per-Johan Jakobsson¹ and Thomas Helleday¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Biomedical Reseearch Foundation Academy of Athens, Athens, Greece, ³Alexander Fleming Biomedical Sciences Research Center, Athens, Greece
Background/Purpose: Rapidly proliferating cells fuel their increased nucleotide demand by boosting one-carbon metabolism, associated with the survival of pathogenic proliferative cells and the release of…
Abstract Number: 1915 • ACR Convergence 2024
Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting
Martha Delgado¹, Cassidy Hernandez-Tamayo², Melissa Wilson² and Leanna Wise³, ¹Los Angeles General Hospital/Keck Medicine of USC, Costa Mesa, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³LAGMC/Keck Medicine of USC, Los Angeles, CA
Background/Purpose: Timely reproductive health conversations in the rheumatology outpatient setting are essential for optimal maternal-fetal health; however, the literature suggests that these conversations happen for…
Abstract Number: 2130 • ACR Convergence 2024
Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Improved disease control for articular manifestations of Rheumatoid arthritis (RA), has resulted in more attention being directed to extra-articular (ExRA) manifestations (cardiovascular events, osteoporosis,…
Abstract Number: 2219 • ACR Convergence 2024
Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort
Tobias Manigold¹, Nicolas Bodmer², Rosoux Elisabeth³, Deborah Markham⁴, Guillaume Fahrni³, Raphael Micheroli⁵, Lucas Bachmann², Jonas Brändli⁶, Fabio Becce⁷ and Thomas Hügle⁸, ¹Department of Rheumatology, Inselspital University Hospital Bern, Bern, Switzerland., Bern, Switzerland, ²Medignition, Zürich, Switzerland, ³3) Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland, Lausanne, Switzerland, ⁴Department of Rheumatology, University Hospital Lausanne (CHUV), Switzerland, Lausanne, Switzerland, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶6) Data Science Team, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, Zürich, Switzerland, ⁷Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁸Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) disease can mimic or interfere with the course of rheumatoid arthritis (RA). Previous studies suggest higher prevalence of Chondrocalcinosis…
Abstract Number: 2236 • ACR Convergence 2024
Relation Between Sociodemographic Factors and Hand Function in Patients with Early Rheumatoid Arthritis
Maria Rydholm¹, Mohaned Hameed², Anna Eberhard², Ankita Sharma², Giovanni Cagnotto² and Carl Turesson², ¹Skåne University Hospital, Malmö, Sweden, ²Lund University, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular involvement of the hands, leading to impaired function. The impact of active inflammation on disability in early…
Abstract Number: 2255 • ACR Convergence 2024
Differences in Pharmacological Prescription to Patients with Recent-onset Arthritis: Analysis from the Gender Perspective
Maryia Nikitsina, María Ahijón Lana and Isidoro González-Álvaro, University Hospital La Princesa, Madrid, Madrid, Spain
Background/Purpose: Nowadays the honing in on sex-specific treatment options is the most productive way to move forward with the larger effort of implementing precision medicine.…
Abstract Number: 2274 • ACR Convergence 2024
Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial
Asger Reinstrup Bihlet¹, Philip G Conaghan², Thomas Boesen³, Mette Arnum Jensen³, Alejandro Castillo Mondragón⁴, Ema Erkocevic Petersen⁴, Cathrine Borgsted Bak⁴ and Thomas EN Jonassen³, ¹NBCD A/S, Soeborg, Denmark, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Synact Pharma ApS, Holte, Denmark, ⁴NBCD A/S, Soborg, Denmark
Background/Purpose: AP1189 is a novel, first-in-class, oral, biased melanocortin (MC)1 and MC3 receptor agonist in development for Rheumatoid Arthritis (RA) treatment. Through multiple actions including…
Abstract Number: 2534 • ACR Convergence 2024
Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics
Juan Vargas¹, Ian Mantel², Jun Inamo³, Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao⁵, Susan Goodman⁶, Kevin Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri¹¹, Trent Woodruff¹², the Accelerating Medicines Partnership (AMP) RA/SLE Network¹³, Michael Holers¹⁴, Laura Donlin¹⁵ and Fan Zhang¹⁶, ¹The University of Colorado, Aurora, CO, ²WEILL CORNELL MEDICINE, New York, NY, ³University of Colorado School of Medicine, Aurora, CO, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University of Queensland, Brisbane, Australia, ¹³AMP RA/SLE consortium, Aurora, CO, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of Colorado, Aurora, CO
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
Abstract Number: 2610 • ACR Convergence 2024
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Johannes Knitza¹, Johanna Mucke², Manuel Grahammer³, Sebastian Kuhn¹, Nicolas Vuillerme⁴, Felix Muehlensiepen⁵, Gerhard Krönke⁶, Georg Schett⁷, Ann-Christin Pecher⁸ and Martin Krusche⁹, and the TELERA Study Group, ¹Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, ²Heinrich-Heine-University, Duesseldorf, Germany, ³ABATON, Berlin, Germany, ⁴AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, ⁵Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, ⁶Rheumatology, Charité, Berlin, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, ⁹III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
Abstract Number: L07 • ACR Convergence 2023
3-year Results of Tapering TNFi to Withdrawal Compared to Stable TNFi Among Rheumatoid Arthritis Patients in Sustained Remission: A Multicenter Randomized Trial
Kaja Kjørholt¹, Nina Sundlisæter¹, Anna-Birgitte Aga¹, Joseph Sexton¹, Inge Christoffer Olsen², Åse Lexberg³, Tor Magne Madland⁴, Hallvard Fremstad⁵, Christian A. Høili⁶, Gunnstein Bakland⁷, Cristina Spada⁸, Hilde Haukeland⁹, Inger Myrnes Hansen¹⁰, Ellen Moholt¹, Karen Holten¹, Till Uhlig¹, Tore Kvien¹, Daniel Solomon¹¹, Désirée van der Heijde¹², Espen Haavardsholm¹ and Siri Lillegraven¹, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Nepal, ³Department of Rheumatology, Drammen Hospital, Vestre Viken HF, Drammen, Norway, ⁴Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁵Department of Rheumatology, Møre og Romsdal Hospital Trust, Ålesund, Norway, ⁶Department of Rheumatology, Østfold Hospital Trust, Moss, Norway, ⁷Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway, ⁸Department of Rheumatology, Revmatismesykehuset AS, Lillehammer, Norway, ⁹Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ¹⁰Deptartment of Rheumatology, Helgelandssykehuset, Mo i Rana, Norway, ¹¹Division of Rheumatology, Brigham and Women's Hospital, Newton, MA, ¹²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Tapering of tumor necrosis factor inhibitor (TNFi) treatment in patients who have reached sustained remission is debated in current guidelines, and further data are…
Abstract Number: L08 • ACR Convergence 2023
Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
Leonie Middelink¹, Renato Chirivi², Helmuth van Es², Eric Meldrum², Peter van Zandvoort², Tirza Bruurmijn², Matthijs Moerland³ and Patrick Round², ¹Middelinc., Utrecht, Netherlands, ²Citryll BV, Oss, Netherlands, ³CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Traps (NETs) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases such as Rheumatoid arthritis (RA) Hidradenitis suppurativa (HS),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].